Coty Inc header image

Coty Inc

COTY

Equity

ISIN null / Valor 1645885

New York Stock Exchange, Inc (2026-05-01)
USD 2.47+0.41%

Coty Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Coty Inc. is a global beauty company with a history that spans over a century, marking its significance in transforming the beauty industry into what it is today. The company boasts a diverse portfolio of over 50 iconic cosmetic, skincare, and fragrance brands. Coty's business strategy is rooted in innovation and excellence, aiming to empower and enable all visions of beauty through its products. The company emphasizes the importance of science and passion as key drivers behind its mission to offer new, innovative, and science-based beauty solutions. Coty Inc. positions itself as a forward-thinking entity in the beauty sector, dedicated to supporting diverse and evolving concepts of beauty that resonate with individuals on a personal level.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (02.04.2026):

Coty Inc — second quarter of fiscal year 2026 (quarter ended December 31, 2025): reported Q2 results were broadly in line with the company’s outlook. Net revenue was $1,678.6 million ( +1% reported; -3% like‑for‑like), adjusted results showed resilience (adjusted operating income $274.3M; adjusted EBITDA $330.2M), and strong cash generation plus the $750M Wella proceeds materially reduced net debt and leverage to near nine‑year lows, while leadership changes and a new "Coty. Curated." strategy were announced.

Top‑line and mix

Q2 net revenues: $1,678.6M (+1% reported; -3% LFL). Prestige (68% of sales) was $1,133.6M (+2% reported; -2% LFL); Consumer Beauty was $545.0M (-2% reported; -6% LFL).

Margins and profitability

Reported gross margin 63.8% (down 290 bps); adjusted gross margin 64.2% (down 260 bps). Reported operating income was $148.2M (down 45%); adjusted operating income was $274.3M (down 18%). Reported net loss attributable to common shareholders was $(126.9)M; adjusted net income was $119.7M.

Earnings per share and adjusted metrics

Reported diluted EPS (common) was $(0.14); adjusted diluted EPS was $0.14. Adjusted EBITDA was $330.2M (down 15% year‑over‑year); adjusted EBITDA margin 19.7% (down 370 bps).

Cash flow and balance sheet

Operating cash flow was $559.7M and free cash flow $513.1M for Q2. Total debt fell to $3,038.1M with financial net debt $2,601.4M, yielding a financial leverage ratio of 2.7x (down from 3.7x the prior quarter), driven primarily by strong cash flow and $750M upfront from sale of Coty’s remaining 25.8% stake in Wella.

Notable one‑offs and adjustments

Q2 included a realized loss on the Wella investment and mark‑to‑market impacts from equity swaps (Total Return Swaps hurt adjusted EPS by $0.04 in Q2 and $0.07 YTD). Non‑GAAP adjustments materially bridge reported losses to positive adjusted results.

Segment performance

Prestige: $1,133.6M in Q2, modest reported growth but -2% LFL; adjusted operating margin 21.8%. Consumer Beauty: $545.0M, pressure in color cosmetics and fragrances (-6% LFL) with adjusted operating margin down to 5.0% and sizable EBITDA decline.

Regional trends

EMEA led reported growth (+3% reported; -4% LFL), Americas declined (~-2% reported; -3% LFL) with U.S. prestige fragrances uneven, and Asia Pacific slightly down (-1% reported; -2% LFL) but with pockets of strength in China and Japan.

Leadership, strategy and portfolio actions

Markus Strobel named Executive Chairman & Interim CEO effective Jan 1, 2026; company launched the "Coty. Curated." strategic framework to sharpen priorities, focus investments and improve execution. Coty is continuing a strategic review of its Consumer Beauty portfolio.

Outlook (Q3 guidance)

Company withdrew prior FY26 EBITDA and FCF guidance and provided only Q3 guidance: expects LFL Q3 revenue to decline mid‑single‑digits (Consumer Beauty weakness), Q3 gross margins to be down 200–300 bps, adjusted EBITDA of $100–110M, roughly breakeven adjusted EPS (ex‑equity swap), and anticipates free cash flow outflow in Q3 (including ~ $30M cash taxes related to the Wella sale).

Investor takeaways

Results show operational pressure in a promotional market and Consumer Beauty sell‑out challenges, but materially improved leverage and strong cash generation provide financial flexibility. Management change and the "Coty. Curated." program signal an increased focus on portfolio prioritization and margin recovery going forward.

Summarized from source with an LLMView Source

Key figures

-50.8%1Y
-79.1%3Y
-75.3%5Y

Performance

54.2%1Y
42.0%3Y
45.0%5Y

Volatility

Market cap

2174 M

Market cap (USD)

Daily traded volume (Shares)

8,786,713

Daily traded volume (Shares)

1 day high/low

6.99 / 6.81

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Amphastar Pharmaceuticals Inc Valor: 24511852
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.36%USD 21.88
Schrodinger Inc
Schrodinger Inc Schrodinger Inc Valor: 51947209
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.60%USD 12.39
International Flavors & Fragrances Inc
International Flavors & Fragrances Inc International Flavors & Fragrances Inc Valor: 941876
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.87%USD 70.81
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.35%USD 2.84
BrightSpring Health Services Inc
BrightSpring Health Services Inc BrightSpring Health Services Inc Valor: 131996976
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.37%USD 47.97
Outset Medical Inc
Outset Medical Inc Outset Medical Inc Valor: 56717137
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.11%USD 4.36
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.59%USD 68.56
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc Protagonist Therapeutics Inc Valor: 33278818
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.61%USD 98.37
Allogene Therapeutics Inc
Allogene Therapeutics Inc Allogene Therapeutics Inc Valor: 43756548
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.94%USD 2.15
Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-24.91%USD 16.11